WRITTEN BY
OnDosis: Precision in every dose for enhanced treatment
Founded as a spinoff from AstraZeneca in 2017, OnDosis aimed to revolutionize oral medication delivery with its unique dosage management technology.
The complexities of developing a product that combined drug formulation, device development and digital health components presented significant challenges.
Through the BioVentureHub, OnDosis benefitted from AstraZeneca’s infrastructure and expertise in various ways:
Strategic advice: Early on, OnDosis leveraged AstraZeneca’s experts, benefiting from their knowledge in areas like regulatory pathways, intellectual property (IP) and formulation development.
Resource utilization: The company borrowed lab equipment from and utilized services from peer companies at the BioVentureHub. This access provided cost-effective solutions for crucial development phases.
Network and recruitment: OnDosis built its team by leveraging the network within the BioVentureHub and AstraZeneca, recruiting individuals seeking dynamic roles in smaller, innovative environments.
Collaborative growth: Engaging in collaborations with other BioVentureHub companies and AstraZeneca itself, OnDosis benefited from a supportive ecosystem, enabling a synergistic approach to R&D and commercial strategies.
Martin Olovsson...... explaining the bridging from the BioVentureHub Community at AstraZeneca, to the new relation, being a BioVentureHub Alumni, situated at GoCo Health Innovation City, while having the "Arrivederci" lecture for the community.
Key facts - From a spinoff to a fast growing commercial company
Since being founded as an AstraZeneca spinoff in 2017, OnDosis has seen remarkable growth at the BioVentureHub, expanding its team to 25 and initiating seven development programs with pharmaceutical partners.
Central challenge: OnDosis faced the intricate task of writing a “new chapter in precision medicine” through developing an intuitive and user-friendly device for flexible and individual dosing of oral solid medicines. This innovation required a synergy of drug formulation, device development, and digital health components – a multifaceted challenge in the pharmaceutical industry.
Key solution: To navigate these complexities, OnDosis capitalized on the expertise available at AstraZeneca. Insights from seasoned professionals in regulatory pathways, intellectual property and formulation development were crucial in guiding their journey.
Impact & achievement: Looking forward to 2026, OnDosis is poised to launch its first combination product in the US. This signifies a pivotal achievement, transforming an innovative concept into a tangible, market-ready solution.
CEO insights and comments on success...
On access to expertise…
"The chance for us to easily meet AstraZeneca experts over a coffee was invaluable. Their advice on whom to consult, which mistakes to avoid, and the best paths to take played a crucial role in our intense early development phase."
On full-circle innovation…
"OnDosis is born from an AstraZeneca idea that they couldn’t develop because they didn't have the program around it. Spinning it out, maturing it externally and then bringing it back in as a mature opportunity. To me, that would be an ultimate example of full circle innovation."
On the supportive and collaborative nature of the BioVentureHub…
"There is a big difference growing up as a lone tree in a field versus growing up as a tree that is part of a forest... Like the forest, the BioVentureHub offers protection, guidance, and a community that fosters growth.”
Having the opportunity to easily meet AstraZeneca experts over a coffee was invaluable. Their guidance in choosing the right consultants, avoiding pitfalls and navigating our development path was fundamental during our initial, critical phase of growth.
OnDosis has an interesting 2026 coming up.
By 2026, OnDosis anticipates the US launch of its first combination product, marking a significant milestone in its journey from an initial idea to a market-ready innovation.
Through the BioVentureHub, OnDosis has not only accelerated its development process but also positioned itself as a key player in precision medicine, embodying the transformative impact of leveraging AstraZeneca infrastructure and expertise for startup growth and innovation.
There is a big difference growing up as a lone tree in a field versus growing up as a tree that is part of a forest... Like the forest, the BioVentureHub offers protection, guidance, and a community that fosters growth.
OnDosis was the first company to grow out of BioVentureHub, and at the same time having a natural landingspot within the ecosystem. The newly opened GoCo House is a perfect place to work with growth, commercialisation and operations.
Martin Olovsson, CEO of OnDosis and Stina Wigren, COO of OnDosis, illustrates that i a perfect way.
Read more about OnDosis: www.ondosis.com
Visit OnDosis at Linkedin: LinkedIn
Read more about BioVentureHub Case Studies : https://www.azbioventurehub.com/
Visit AstraZeneca BioVentureHub at Linkedin: LinkedIn
Sign up on the BioVentureHub Newsletter - click this link